Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track EIKN with free AI briefings, catalyst countdowns, and dilution alerts.

EIKN · Eikon Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$461.7M Cash on Hand
20.7mo Cash Runway
Follow EIKN by email Get an email when EIKN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about EIKN, unsubscribe in one click. Privacy

📣 What EIKN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Resiquimod Sulfate (BDB001) Advanced Melanoma Phase 2/3 · NCT06697301 Recruiting
Nab-paclitaxel Non Small Cell Lung Cancer (Squamous or Non Squamous) Phase 2/3 · NCT07365319 Recruiting
WRN Inhibitor EIK1005 Advanced Solid Tumors Phase 1/2 · NCT07262619 Recruiting
PARP1 Inhibitor IMP1734 Advanced Solid Tumor Phase 1/2 · NCT06253130 Recruiting
PARP1 Inhibitor EIK1004 Advanced Solid Tumors Phase 1/2 · NCT06907043 Recruiting
Toll-like Receptor 7/8 Agonist BDB018 Tumor, Solid Phase 1 · NCT04840394 Completed

Also used in these trials (approved or third-party drugs, not EIKN's own candidates): Pemetrexed Disodium, Pembrolizumab, Paclitaxel, Carboplatin, Atezolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

EIKN holds $461.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $67.1M/quarter from operations, an estimated runway of 20.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 11 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EIKN files for a raise →

👥 Who Owns EIKN

Insiders 18.3% Other 5%+ holders 24.4% Institutions (127 holders) 57.3% Public and other holders 0%
HolderTypeShares% of sharesAs of
Tim Kutzkey 5%+ holder (13D) 6,353,712 11.73% 2026-02-06
Column Group IV GP, LP
10% owner
Insider 5,869,343 10.84% 2026-09-03
FMR LLC Institution (13G, 5%+) 5,520,152 10.19% 2026-09-30
James B. Tananbaum 5%+ holder (13G) 4,148,519 7.66% 2026-02-04
BlackRock Portfolio Management LLC Institution (13G, 5%+) 3,002,737 5.54% 2026-03-31
Innovation Endeavors III LP 5%+ holder (13G) 2,723,226 5.03% 2026-03-31
Lux Venture Partners V, LLC
10% owner
Insider 2,294,653 4.24% 2026-02-04
Josh Wolfe
Director, 10% owner
Includes shares also reported by Lux Venture Partners V, LLC, counted once
Insider 2,294,653 4.24% 2026-02-04
Foresite Capital Management IV, LLC
10% owner · +34,185 options
Insider 1,318,983 2.44% 2026-02-04
Roger M Perlmutter
Chief Executive Officer and Director, Di · +268,176 options
Insider 284,857 0.53% 2026-02-06
Kenneth C Frazier
Director · +25,873 options
Insider 111,111 0.21% 2026-02-04
Alfred Lloyd Jr. Bowie
Chief Financial Officer · +67,044 options
Insider 51,572 0.10% 2026-02-04

Share count 54,165,030 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full EIKN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EIKN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.